“Lilly delivered strong revenue growth in the second quarter, building on the momentum of Trulicity, Taltz and the other new products in our portfolio,” said David A. Ricks, Lilly’s chairman, president and CEO.
“To deliver on our mission and maximize our opportunity, we have four key priorities — launching with excellence, replenishing the pipeline, driving productivity, and building talent and capability in our core areas of focus.”
The company has reported the net income of $1,008.million, compared to $747.7 with the same period last year, which represents an increase of 35%.
The company said it would pursue new standard-of-care changing therapies that target tumor dependencies in molecularly enriched populations, build rational combinations that overcome resistance, and develop next-generation immunotherapies